Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

Andrea B. Apolo, MD
Published: Wednesday, Jun 28, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

In the combination of cabozantinib plus nivolumab (Opdivo) and cabozantinib plus ipilimumab (Yervoy), the typical side effects of each agent were shown. There was no synergy between the toxicities though, which is an encouraging sign, says Apolo.

The recommended phase II dose is cabozantinib at 40 mg (CHECK), nivolumab at 3 mg/kg, and ipilimumab at 1 mg/kg.
 
SELECTED
LANGUAGE


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

In the combination of cabozantinib plus nivolumab (Opdivo) and cabozantinib plus ipilimumab (Yervoy), the typical side effects of each agent were shown. There was no synergy between the toxicities though, which is an encouraging sign, says Apolo.

The recommended phase II dose is cabozantinib at 40 mg (CHECK), nivolumab at 3 mg/kg, and ipilimumab at 1 mg/kg.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x